Pegaptanib sodium for the treatment of diabetic macular oedema
Please note that, following on from information provided to NICE by the company in July 2011, the appraisal of Pegaptanib sodium for the treatment of diabetic macular oedema [ID452] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Decision Selected
Process TA
Referral date 01 March 2011
Topic area
  • Endocrine, nutritional and metabolic
  • Eye
Description

NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

Scoped within Batch 16

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager:

Lori Farrar

Technical Lead: Helen Tucker

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Please note that, following on from information provided to NICE by the company in July 2011, the appraisal of Pegaptanib sodium for the treatment of diabetic macular oedema [ID452] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
29 July 2011 NICE has been informed by the manufacturer of Pegaptanib, Pfizer, that they have withdrawn their licensing application for the above indication. Therefore this appraisal topic has been suspended and the appraisal committee agenda topic that was due to take place on 8 November 2011 has been cancelled.

NICE will continue to monitor any development and update this webpage if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual